Zydus's oral GLP-1 agonist approved for Indian clinical trials
This article was originally published in Scrip
Executive Summary
Zydus Cadila has received permission from the Drugs Controller General of India to start Phase I clinical trials for its oral glucagon-like peptide-1 (GLP-1) agonist for diabetes, ZYOG1. The molecule appears to be only the second oral GLP-1 analogue to enter clinical development after Novo Nordisk's NN9924.